TENNOR THERAP-B

TenNor Therapeutics (Suzhou) Limited is a biotechnology company focused on the discovery, development, and commercialization of differentiated therapies for diseases linked to bacterial infections and bacterial metabolism. Its pipeline includes Rifasutenizole (TNP-2198) for Helicobacter pylori infection, Rifaquizinone (TNP-2092) injection for periprosthetic joint infection (PJI), acute bacterial skin and skin structure infections (ABSSSI), and left ventricular assist device (LVAD) infection, and oral TNP-2092 for gut bacterial metabolism-related conditions such as hepatic encephalopathy (HE) and irritable bowel syndrome with diarrhea (IBS-D). The company is also developing TNP-2092 topical for drug-resistant bacterial strains and biofilm infections, TNBi-1 for H. pylori, TNBi-2 for nontuberculous mycobacterial pulmonary disease (NTM-PD), and TNBm-1 for metabolic disease. Founded in 2012, it is headquartered in Suzhou, China.